Loading

Phycoil Biotechnology International Inc.

June 16, 2025
Company Presentation
Brain Health
Phycoil Biotechnology International Inc., based in Fremont, California, is an innovative biotech company leveraging a proprietary microbial platform to develop sustainable, plant-based bio-products. With a unique collection of proprietary strains and expertise in synthetic and industrial biotechnology, Phycoil produces high-value omega-3, -6, and -9 fatty acids and functional ingredients for nutraceuticals, personal care, and food applications. Its advanced fermentation technologies use microalgae cultivated via eco-conscious processes that preserve marine ecosystems. Phycoil’s product offerings target key health areas such as inflammation and brain health, delivering bioactives that support cognitive performance and immune balance. Backed by a robust patent portfolio and international operations, including its South Korean subsidiary, Phycoil is advancing environmentally responsible, health-promoting innovations at global scale.
Phycoil Biotechnology International Inc.
Company HQ City: Fremont
Company HQ State: CA
Company HQ Country: United States
Year Founded: 2009
Lead Product in Development: A unique portfolio of rare and structurally optimized omega-3, -6, and -9 fatty acids, developed through proprietary microalgae fermentation. These bioactives are targeted for clinically relevant applications in cardiovascular health, cognitive function, and healthy aging—addressing key areas of global unmet need.

CEO

Dr. Chung Soon Im

Development Phase of Lead Product

Pre-Clinical

Number of Unlicensed Products Looking for Licensing

5 unlicensed products

When you expect your next catalyst update?

Phycoil’s next major inflection point is the scale-up and commercialization of its lead omega-3, -6, and -9 fatty acid formulation, with initial clinical validation studies planned for Q3 2025. This milestone will enable strategic licensing opportunities and commercial partnerships in the nutraceutical and functional health sectors. Additionally, expansion of our biomanufacturing capacity in Korea is expected to further de-risk production and accelerate go-to-market timelines.

What is your next catalyst (value inflection) update?

September 2025
Visit Website
Primary Speaker
Chung Soon Im
Chung Soon Im, PhD
CEO
Phycoil Biotechnology International Inc.
Back to Session List

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS